A Phase 1 interventional study of AGA2115 and Placebo in Osteogenesis Imperfecta, sponsored by Angitia Incorporated Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.
Sponsored by Angitia Incorporated Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Osteogenesis Imperfecta with a site in United States — 4 open to participants now, 11 under way, 4 of them phase 3. Osteogenesis Imperfecta · United States.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 36th registered.
84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
Browse Osteogenesis Imperfecta studies →4 of the 38 studies in Osteogenesis Imperfecta with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Belgium, China and 3 more countries
Ages 5–19
Angitia Incorporated Limited · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
Hospital for Special Surgery, New York · Sites in United States
Ages 6–100 · Healthy volunteers
Baylor College of Medicine · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 9 · Phase 4 2
First in 1991; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.
Median enrollment 63 across the 28 interventional studies, 82 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 38 have an industry lead sponsor. The 10 most frequent:
Angitia Incorporated Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Angitia Incorporated Limited has 2 studies filed under Osteogenesis Imperfecta — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteogenesis Imperfecta with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972551Phase 3AmgenStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | 2027-05-04 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT04815564Baylor College of MedicineClear Aligners for the Treatment of Dental Malocclusion in OI | 2027-08-01 |
| NCT05317637Baylor College of MedicineCardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 | 2027-08-31 |
| NCT07062588Angitia Incorporated LimitedOsteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A, up to 6 single ascending dose cohorts. In Part B, up to 3 multiple ascending dose cohorts.
Drug: AGA2115
Participants will receive matching placebo.
Drug: Placebo
In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort). In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.
In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort). In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Number of participants with treatment-emergent adverse events (TEAEs)
Clinically significant changes in clinical laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs) will be recorded as TEAEs.
Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)
Maximum observed concentration (Cmax) of AGA2115
Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)
Time to maximum observed concentration (Tmax) of AGA2115
Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)
Area under the concentration time curve (AUC) of AGA2115
Time frame: Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Oct 2024, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Humanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115)
Angitia Incorporated Limited